This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.Need a new registration confirmation email? Click here

Abbott Laboratories (ABT): Today's Featured Health Care Winner

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

Abbott Laboratories (
ABT) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day up 0.5%. By the end of trading, Abbott Laboratories rose 33 cents (1%) to $33.33 on average volume. Throughout the day, 14.6 million shares of Abbott Laboratories exchanged hands as compared to its average daily volume of 14.5 million shares. The stock ranged in a price between $32.96-$33.45 after having opened the day at $32.96 as compared to the previous trading day's close of $33. Other companies within the Health Care sector that increased today were:
Keryx Biopharmaceuticals (
KERX), up 38%,
Cormedix (
CRMD), up 22.5%,
Ventrus Biosciences (
VTUS), up 20.1%, and
Theratechnologies (
THER), up 19.8%.

EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Abbott Laboratories engages in the discovery, development, manufacture, and sale of health care products worldwide. Abbott Laboratories has a market cap of $51.83 billion and is part of the drugs industry. The company has a P/E ratio of 6.5, below the S&P 500 P/E ratio of 17.7. Shares are down 49.9% year to date as of the close of trading on Monday. Currently there are eight analysts that rate Abbott Laboratories a buy, no analysts rate it a sell, and 11 rate it a hold.

TheStreet Ratings rates Abbott Laboratories as a
hold. The company's strengths can be seen in multiple areas, such as its revenue growth and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income, a generally disappointing performance in the stock itself and feeble growth in the company's earnings per share.